Immunogenicity of panitumumab in combination chemotherapy clinical trials

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Weeraratne, Dohan ^a   Chen, Alin ^a   Pennucci, Jason J ^a   Wu, Chi Yuan ^a   Zhang, Kathy ^a   Wright, Jacqueline ^a   Pérez Ruixo, Juan J ^a   Yang, Bing Bing ^a   Kaliyaperumal, Arunan ^a   Gupta, Shalini ^a   Swanson, Steven J ^a   Chirmule, Narendra ^a   Starcevic, Marta ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; NEUTRALIZING ANTIBODY; OXALIPLATIN; PANITUMUMAB; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ANTIBODY DETECTION; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; COMPARTMENT MODEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GENE MUTATION; HUMAN; IMMUNOGENICITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TOXICITY; TREATMENT OUTCOME; VALIDATION STUDY; VOMITING; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HOSPITALIZATION; IMMUNOLOGY; INCIDENCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; HUMANS; INCIDENCE; ORGANOPLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX;

EID: 80655132139     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-17     Document Type: Article

References (25)

1. Vectibix® (panitumumab) prescribing information. 2011, Amgen Inc, Thousand Oaks, CA.
2. EPARs for authorised medicinal products for human use. , http://www.emea.europa.eu/humandocs/Humans/EPAR/vectibix/vectibix.htm
3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705. 10.1200/JCO.2009.27.4860, 20921465.
4. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713. 10.1200/JCO.2009.27.6055, 20921462.
5. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007, 25(5):555-561. 10.1038/nbt1303, 17483842.
6. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9(10):767-774. 10.1038/nrd3229, 20811384.
7. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36(1):3-10. 10.1016/j.ymeth.2005.01.001, 15848070.
8. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66(7):921-926. 10.1136/ard.2006.065615, 1955110, 17301106.
9. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007, 27(3):269-274.
10. Khazaeli M, LoBuglio A, Falcey J, Paulter V, Fetzer M, Waksal H. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IM-C225, used to treat epidermal growth factor receptor-positive tumor [abstract]. Proc Am Soc Clin Oncol 2000, 19:Abst 808.
11. Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007, 13(3):986-993. 10.1158/1078-0432.CCR-06-1542, 17289894.
12. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007, 25(24):3644-3648. 10.1200/JCO.2007.11.7812, 17704414.
13. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008, 358(11):1109-1117. 10.1056/NEJMoa074943, 2361129, 18337601.
14. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 2010, 28(8):863-867. 10.1038/nbt.1651, 3077421, 20657583.
15. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006, 29(1):1-9. 10.1097/01.cji.0000192105.24583.83, 16365595.
16. Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, Swanson SJ, Mullenix MC. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007, 178(11):7467-7472.
17. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(8):1351-1357. 10.1200/JCO.2008.21.7828, 20142600.
18. Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2011, 10(3):171-177. 10.1016/j.clcc.2011.03.022, 21855038.
19. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
20. Barger TE, Zhou L, Hale M, Moxness M, Swanson SJ, Chirmule N. Comparing exponentially weighted moving average and run rules in process control of semiquantitative immunogenicity immunoassays. AAPS J 2010, 12(1):79-86. 10.1208/s12248-009-9166-4, 2811647, 20012239.
21. Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, Rodriguez R, Chow A. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 2009, 49(10):1142-1156. 10.1177/0091270009344989, 19723673.
22. Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, Perez Ruixo JJ. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010, 49(11):729-740. 10.2165/11535970-000000000-00000, 20923247.
23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001, 28(2):171-192. 10.1023/A:1011555016423, 11381569.
24. Eloxatin® (oxaliplatin) prescribing information. 2009, sanofi aventis, Bridgewater, NJ.
25. Camptosar® (irinotecan hydrochloride) prescribing information. 2010, Pharmacia & Upjohn Co. Division of Pfizer Inc., New York, NY.